ZTS logo

Zoetis Inc. Stock Price

NYSE:ZTS Community·US$47.3b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 188 Fair Values set on narratives written by author

ZTS Share Price Performance

US$111.22
-44.77 (-28.70%)
US$151.00
Fair Value
US$111.22
-44.77 (-28.70%)
26.3% undervalued intrinsic discount
US$151.00
Fair Value
Price US$111.22
AnalystConsensusTarget US$151.00
AnalystHighTarget US$184.42
AnalystLowTarget US$127.00

ZTS Community Narratives

·
Fair Value US$151 26.3% undervalued intrinsic discount

ZTS: Global Demand Trends Will Drive Earnings Consistency In Coming Quarters

5users have liked this narrative
0users have commented on this narrative
81users have followed this narrative
·
Fair Value US$184.42 39.7% undervalued intrinsic discount

Simparica Trio And Global Animal Demand Will Transform Markets

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
·
Fair Value US$127 12.4% undervalued intrinsic discount

Regulatory Scrutiny And Trade Barriers Will Limit Market Potential

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative

Trending Discussion

Updated Narratives

ZTS logo

ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside

Fair Value: US$184.42 39.7% undervalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ZTS logo

ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk

Fair Value: US$127 12.4% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
ZTS logo

ZTS: Future Pet Osteoarthritis Pipeline Will Support Premium Multiple Potential

Fair Value: US$151 26.3% undervalued intrinsic discount
81 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued established dividend payer.

1 Risk
5 Rewards

Zoetis Inc. Key Details

US$9.5b

Revenue

US$2.7b

Cost of Revenue

US$6.8b

Gross Profit

US$4.1b

Other Expenses

US$2.7b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
May 07, 2026
6.36
71.89%
28.23%
271.9%
View Full Analysis

About ZTS

Founded
2012
Employees
14500
CEO
Kristin Peck
WebsiteView website
www.zoetis.com

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Recent ZTS News & Updates

Narrative Update May 03

ZTS: Share Repurchases And Capital Discipline Will Support Medium-Term Upside

Analysts have modestly trimmed their Zoetis fair value estimate by about $3 to $184, reflecting mixed updates to revenue growth, margins, and long term P/E assumptions after recent shifts in price targets and ratings across the Street. Analyst Commentary Recent research updates on Zoetis reflect a mix of reduced price targets, a downgrade on growth concerns, and fresh bullish coverage.
Narrative Update Apr 19

ZTS: Fair View Weighs Organic Growth Concerns Against Pipeline Execution Risk

Analysts have trimmed the Zoetis fair value estimate by $3 to $127, reflecting a mix of cautious views around organic growth and slightly adjusted assumptions for future P/E, revenue growth, and profitability, even as some firms maintain a bullish stance on the stock. Analyst Commentary Recent Street research around Zoetis shows a split tape, with several bearish analysts focusing on weaker organic growth trends and execution risk, even as others remain constructive on the long term story.

Recent updates

No updates